tetano
Editor, Senior Moderator
Cell Immunol. 2016 Apr 9. pii: S0008-8749(16)30020-X. doi: 10.1016/j.cellimm.2016.04.004. [Epub ahead of print]
[h=1]RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.[/h] Cao W[SUP]1[/SUP], Liepkalns JS[SUP]2[/SUP], Kamal RP[SUP]3[/SUP], Reber AJ[SUP]2[/SUP], Kim JH[SUP]2[/SUP], Hofstetter AR[SUP]4[/SUP], Amoah S[SUP]3[/SUP], Stevens J[SUP]5[/SUP], Ranjan P[SUP]2[/SUP], Gangappa S[SUP]2[/SUP], York IA[SUP]2[/SUP], Sambhara S[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced antibody and T cell responses and conferred protection against lethal challenge with a homologous H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to increase the immunogenicity of recombinant H7 hemagglutinin.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Antibody responses; Cell-mediated immunity; H7HA; Influenza; Mouse model; Protective immunity; RIG-I ligand
PMID: 27106062 [PubMed - as supplied by publisher]
[h=1]RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.[/h] Cao W[SUP]1[/SUP], Liepkalns JS[SUP]2[/SUP], Kamal RP[SUP]3[/SUP], Reber AJ[SUP]2[/SUP], Kim JH[SUP]2[/SUP], Hofstetter AR[SUP]4[/SUP], Amoah S[SUP]3[/SUP], Stevens J[SUP]5[/SUP], Ranjan P[SUP]2[/SUP], Gangappa S[SUP]2[/SUP], York IA[SUP]2[/SUP], Sambhara S[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Avian H7N9 influenza virus infection with fatal outcomes continues to pose a pandemic threat and highly immunogenic vaccines are urgently needed. In this report we show that baculovirus-derived recombinant H7 hemagglutinin protein, when delivered with RIG-I ligand, induced enhanced antibody and T cell responses and conferred protection against lethal challenge with a homologous H7N9 virus. These findings indicate the potential utility of RIG-I ligands as vaccine adjuvants to increase the immunogenicity of recombinant H7 hemagglutinin.
Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Antibody responses; Cell-mediated immunity; H7HA; Influenza; Mouse model; Protective immunity; RIG-I ligand
PMID: 27106062 [PubMed - as supplied by publisher]